Document is current
Any future updates will be listed below
-
Authors
Scofield, Ditte https://orcid.org/0000-0003-3202-7374
Weis, Nina https://orcid.org/0000-0002-3133-2724
Meddis, Alessandra
Storgaard, Merete https://orcid.org/0000-0001-6110-5963
Pedersen, Gitte
Johansen, Isik S. https://orcid.org/0000-0002-2189-9823
Katzenstein, Terese L. https://orcid.org/0000-0002-2233-500X
Graugaard, Christian https://orcid.org/0000-0003-0217-3637
Omland, Lars H. https://orcid.org/0000-0002-5338-8948
Frisch, Morten https://orcid.org/0000-0002-3864-8860
Moseholm, Ellen https://orcid.org/0000-0002-7195-8641
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Accepted: 6 June 2025
First Online: 14 June 2025
Declarations
:
: EM reports unrestricted grants from the Novo Nordisk Foundation and Gilead Sciences, outside of the submitted work, and personal fees from Gilead, Bristol Myers Squibb, and GlaxoSmithKline, outside of the submitted work: honorarium paid to her institution. TLK reports personal fees and grants from ViiV/GlaxoSmithKline, MSD, Gilead, CLS Behring, Takeda and Vertex, outside of the submitted work. The remaining authors declare no competing interest.
: The SHARE study has been approved by the Danish Data Protection Agency (approval no. P2021-167). Approval from the Danish National Committee on Health Ethics was not required as no biomedical interventions were part of the study.
: All participants provided informed consent before participation.
